AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$EW

BOBO DONALD E JR sold $2.0M of EW (indirect holdings)

BOBO DONALD E JR (CVP,Strategy/Corp Development) sold 23,145 indirectly-held shares of Edwards Lifesciences Corp (EW) at $86.42 ($2.00M total) on 2026-05-27.

Original reporting
SEC EDGAR · BOBO DONALD E JR
Published May 27, 2026, 11:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

Near-term trading impact is likely limited to sentiment/positioning rather than fundamentals, given no accompanying earnings, guidance, trial, or deal information.

02

Market read

A disclosed insider sale can cause brief negative read-through, but without fundamental catalysts it is unlikely to drive a durable repricing.

03

What to watch

The filing notes indirect ownership and does not confirm whether the sale was part of broader planned selling beyond the stated lack of a pre-arranged 10b5-1 plan; also, one Form 4 does not establish a trend.

Relevance 6/10Timing: Same-day/next-session sentiment check; likely limited follow-through.

Background

The article is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences, filed the same day as the sale.

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences officer BOBO DONALD E JR sold 23,145 shares in an open-market transaction worth about $2.0M, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 insider sales are common and often non-informational; absence of a stated 10b5-1 plan can increase interpretation risk, but the filing provides no new company-specific operational or financial information.

Market effects

Sector

Minimal; one-off insider sale in a medical device/healthcare name typically does not reset sector expectations.

Regional

None indicated; transaction is company-specific and US-listed.

Global

None indicated; no international deal/regulatory/drug-trial content.

Counterpoint

What could challenge this read

Insider sales frequently reflect diversification, taxes, or routine liquidity needs and may not signal negative fundamentals—especially with a single transaction size.

Key entities

  • issuer
    Edwards Lifesciences Corp

    Subject of the SEC Form 4 insider sale by an officer (CVP, Strategy/Corp Development).

  • insider
    BOBO DONALD E JR

    Officer who executed an open-market sale of 23,145 shares on 2026-05-27.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EW insider trading history →

Related articles

OCT 26
$EWHighAI 9/10

Edwards Expands Pascal System to Tricuspid Valve Disease

Edwards Lifesciences (EW) received FDA approval to expand its Pascal system for tricuspid valve disease, making it the only U.S. company offering transcatheter therapies for both mitral and tricuspid valves. The Pascal system is part of Edwards' fastest-growing TMTT unit, which saw $195.9M in Q2 sales, up 43% YoY. The company also announced a voluntary recall of four lots of its Commander M Delivery System due to safety concerns.

ocbj.com2 min
OCT 22
$EWHigh

Edwards secures FDA approval for tricuspid valve repair system

Edwards Lifesciences received FDA approval for its PASCAL Precision tricuspid valve repair system, expanding its transcatheter valve portfolio. The device is for patients with severe tricuspid regurgitation at intermediate or higher surgical risk. Edwards is now the sole US manufacturer offering both mitral and tricuspid valve repair and replacement options. The company also gained FDA clearance for the PASCAL Ace with Capture Clarity system for mitral TEER procedures.

medicaldevice-network.com2 min
OCT 21
$EWHigh

Edwards Wins Approval for Pascal Tricuspid Valve Repair System

Edwards Lifesciences (EW) received FDA approval for its Pascal Precision system to repair tricuspid valves, making it the only U.S. company offering transcatheter repair and replacement for both mitral and tricuspid valves. The Pascal system is part of Edwards' fastest-growing segment, transcatheter mitral and tricuspid therapies (TMTT). Shares of EW were trading at $88.15 with a market cap of $50.7 billion.

ocbj.com1 min
OCT 19
$EWMed

FDA Alert Follows Death Linked to Edwards Device

The FDA issued a safety alert for Edwards Lifesciences' Sapien M3 valve delivery systems after three balloon bursts, including one death. Edwards advised customers to return affected devices. Shares (NYSE: EW) fell 1.3% to $86.94 since the Oct. 15 alert.

ocbj.com1 min
OCT 17
$EWMed

Four Lots of Edwards Mitral Valve Delivery Systems Pulled After Balloon Bursts Linked to One Patient Death

Edwards Lifesciences recalled four lots of its Commander M delivery system after balloon bursts during procedures, linked to one death and one injury. The FDA issued an Early Alert, advising hospitals to stop using the affected lots. The system is used for transcatheter mitral valve replacement in patients unsuitable for surgery. Edwards shares were down less than 1% on Oct. 16.

medicaldaily.com7 min